Each represents a Breeoot member whose outcome depended on finding what standard medicine was not looking for. The diagnoses were not exotic. The tools exist. The difference was knowing to use them.
All cases anonymised. Data adjusted to protect member privacy.
A first round of weight-loss medication had reduced body fat from 31% to 27% — a meaningful start, but well short of the clinical target. The lipid profile remained incomplete, obstructive sleep apnea continued to require CPAP, and body composition was stalling. The picture was partial improvement — not resolution.
An endocrinologist reviewed the full metabolic picture and determined that the original weight-loss medication was not the right fit for this patient’s biology. A better-matched agent was selected. A clinical nutrition specialist built a protocol around his specific markers. A structured physical training programme was added alongside.
Body fat reduced from 31% to 22% — a 9 percentage-point reduction and a clinically meaningful shift in body composition. Lipid profile normalised. Sleep apnea resolved; CPAP discontinued. Currently on no other medications and continuing successfully within the metabolic programme.
By every standard metric, a model of health: strict with preventive care, great physical shape, no overweight, good muscle mass, highly active — including in extreme sports. He came to Breeoot with minimal expectations and no identified concerns.
A proactive whole-exome analysis identified an occult genetic condition driving elevated systemic inflammation. The downstream consequence: significant osteoporosis — entirely unexpected given his age and fitness. For someone engaged in extreme sports, the fracture risk was not hypothetical.
A targeted medication — unavailable through the standard public health system — was identified and prescribed. The genetic condition is now managed and monitored. A fracture that could have ended his active life was pre-empted by a test he didn’t know he needed.
Fit, health-aware, attending annual private screening at a leading hospital. On high-potency statins with LDL-cholesterol well-controlled below 100 mg/dL. Annual stress tests returned normal. Strong family history of premature cardiovascular disease — but everything measurable appeared managed.
Breeoot’s assessment extended beyond a standard lipid panel to measure additional atherogenic particles not routinely evaluated. The results prompted direct coronary imaging. What it showed was alarming: significant atherosclerotic blockades across multiple coronary arteries — several close to complete occlusion. Nothing in her annual screening had suggested this.
She was referred for bypass surgery. A PCSK9 inhibitor was added to address ongoing atherosclerosis risk. A myocardial infarction that was weeks or months away was prevented. This case is the clearest demonstration of why a well-controlled LDL is not, by itself, enough.
Strong family history of type 2 diabetes — both parents and his older brother diabetic. Understandably anxious. But reassured every year: A1c consistently 4.9–5.1%, indicating excellent glucose control. He appeared to have avoided the family pattern.
Continuous glucose monitoring showed higher glucose levels throughout the day than the blood test suggested. CGM-calculated A1c: 6.2% — pre-diabetic range. The discrepancy traces back to G6PD deficiency, a common enzymatic condition that causes standard blood-based A1c to systematically underestimate true glucose exposure by 1.0–1.3%. The standard test had been telling him he was fine for years.
His actual metabolic status — pre-diabetic — is now understood. Monitoring has been restructured around continuous glucose data that is reliable for his biology. Early intervention is now possible, at the stage where it still makes a meaningful difference.
A 30-minute call to understand your current health picture, what the gaps are, and whether Breeoot is the right fit. No obligation.
Schedule a Meeting